Back to School: How biopharma can reboot drug development. Access exclusive analysis here
VIRS will acquire Avid, a privately held developer of antiviral therapies, for $1.25 million in cash
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury